These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38721108)

  • 1. Covid Antibody Titers in Cancer Patients Following Vaccination with ChAdOx1 nCOV-19 Vaccine.
    Chavan A; Shriyan B; Chavan P; Shirsat A; Gavhane U; Pillai B; Bhat V; Dhamne C; Gota V
    South Asian J Cancer; 2024 Jan; 13(1):33-37. PubMed ID: 38721108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, immunogenecity and effectiveness of ChAdOx1 nCoV-19 vaccine during the second wave of pandemic in India: a real-world study.
    Chavan P; Dey R; Castelino R; Kamble A; Poladia P; Bagal R; Jadhav M; Shirsat A; Chavan A; Dhumal S; Kumar S; Krishnamurty MN; Bhat V; Bhattacharjee A; Gota V
    Drug Metab Pers Ther; 2023 Sep; 38(3):227-236. PubMed ID: 37098129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study.
    Teeyapun N; Luangdilok S; Pakvisal N; Sainamthip P; Mingmalairak S; Poovorawan N; Sitthideatphaiboon P; Parinyanitikul N; Sriuranpong V; Namkanisorn T; Inthasuwan P; Angspatt P; Wongchanapat P; Bamrungnam A; Leeleakpai N; Uttha S; Jaichum S; Kongkaew P; Suksanong C; Veranitinun R; Prasomphol A; Sartsuk C; Patcharajutanon C; Preaprang S; Choengsamor H; Phongwan R; Preeyasaksa C; Phaibulvatanapong E; Suntronwong N; Yorsaeng R; Vichaiwattana P; Wanlapakorn N; Kerr SJ; Poovorawan Y; Wanchaijiraboon P; Tanasanvimon S
    EClinicalMedicine; 2022 Oct; 52():101608. PubMed ID: 35971500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
    Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
    Kulkarni PS; Padmapriyadarsini C; Vekemans J; Bavdekar A; Gupta M; Kulkarni P; Garg BS; Gogtay NJ; Tambe M; Lalwani S; Singh K; Munshi R; Meshram S; Selvavinayagam TS; Pandey K; Bhimarasetty DM; Ramakrishnan SR; Bhamare C; Dharmadhikari A; Budhawant C; Bonhomme CJ; Thakar M; Kurle SN; Kelly EJ; Gautam M; Gupta N; Panda S; Bhargava B; Poonawalla CS; Shaligram U; Kapse D; Gunale B
    Hum Vaccin Immunother; 2024 Dec; 20(1):2304974. PubMed ID: 38512394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral antibody response to the first dose of the ChAdOx1 nCoV-19 vaccine in Asian patients undergoing hemodialysis.
    Tung KT; Peng YS; Hsu SP; Wu HY; Chiu YL; Yang JY; Pai MF; Shu KH; Pan SY; Lu HM; Lin WY; Liao CH; Chu FY; Tsai WC
    Hemodial Int; 2022 Jul; 26(3):369-376. PubMed ID: 35411681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
    Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ;
    Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports.
    Sah MK; Singh BM; Sinha P; Devkota P; Yadav SK; Shrestha J; Shrestha A
    J Med Case Rep; 2022 May; 16(1):182. PubMed ID: 35524323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study.
    Kang ES; Oh JS; Lee EJ; Hong S; Ahn SM; Lee CK; Yoo B; Kim YG
    J Korean Med Sci; 2023 Apr; 38(14):e109. PubMed ID: 37038645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
    Flaxman A; Marchevsky NG; Jenkin D; Aboagye J; Aley PK; Angus B; Belij-Rammerstorfer S; Bibi S; Bittaye M; Cappuccini F; Cicconi P; Clutterbuck EA; Davies S; Dejnirattisai W; Dold C; Ewer KJ; Folegatti PM; Fowler J; Hill AVS; Kerridge S; Minassian AM; Mongkolsapaya J; Mujadidi YF; Plested E; Ramasamy MN; Robinson H; Sanders H; Sheehan E; Smith H; Snape MD; Song R; Woods D; Screaton G; Gilbert SC; Voysey M; Pollard AJ; Lambe T;
    Lancet; 2021 Sep; 398(10304):981-990. PubMed ID: 34480858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
    Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G;
    Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
    Iwata S; Pollard AJ; Tada Y; Omoto S; Shibata RY; Igarashi K; Hasegawa T; Ariyasu M; Sonoyama T
    Sci Rep; 2024 Apr; 14(1):9830. PubMed ID: 38684712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study.
    Nordström P; Ballin M; Nordström A
    Lancet Reg Health Eur; 2021 Dec; 11():100249. PubMed ID: 34693387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis.
    Ling TC; Chen PL; Li NY; Ko WC; Sun CY; Chao JY; Shieh CC; Shen CF; Wu JL; Huang TC; Chao CH; Wang JR; Chang YT
    Microbiol Spectr; 2023 Feb; 11(2):e0344522. PubMed ID: 36809164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
    Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.